bioMmune Technologies Inc  

(Public, CVE:IMU)   Watch this stock  
Find more results for Patrick D. Pearson
+0.010 (2.04%)
Jul 22 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.48 - 0.50
52 week 0.23 - 0.57
Open 0.50
Vol / Avg. 0.00/29,810.00
Mkt cap 16.27M
P/E     -
Div/yield     -
EPS -0.04
Shares 31.90M
Beta 1.02
Inst. own     -

Key stats and ratios

Q1 (Feb '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -72.78% -63.38%
Return on average equity -77.77% -67.52%
CDP Score - -


1780-400 Burrard St
+1-604-6886775 (Phone)
+1-604-6886995 (Fax)

Website links


bioMmune Technologies Inc., formerly MC Partners Inc., is a biopharmaceutical company. The Company is a research and development issuer. The Company is engaged in the research and development of products for the treatment of cancers, and for improvement of the immune system. The Company operates in the segment of biotechnology research and development. The Company focuses on cancer, infectious and autoimmune diseases. It offers various technologies, such as Major Histocompatibility Complex I (MHC I), a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells, where the fragments are then exposed to the immune system's T Cells; CD74, a chaperone protein that is involved in the presentation of MHC I and MHC II molecules on cell surfaces, and Calcium Channel Blockers, which are methods and agents that modulate voltage-gated calcium channels.

Officers and directors

Karoly Nikolich Ph.D. Chairman of the Board
Age: 56
Patrick W. Gray Ph.D. President, Chief Executive Officer
Age: 55
Judi Dalling Chief Financial Officer, Secretary
Jens Biertumpel Director
Terry Pearson Ph.D. Director
Age: 69